anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a homogenous population of parasite cells, wherein the cells are not mosquito cells, capable of prolonged culture in vitro. Fractions from the cells, both cellular and non-cellular are also provided. Further provided is a method of treating or preventing parasite involvement with an animal comprising administering immunogenic amounts of the parasite cells of the invention or fractions derived from the cells to the animal, thereby treating or preventing the parasite involvement with the animal. Further provided is a method of detecting the presence of a parasite in an animal, comprising contacting either the parasite cells or cell fractions of the invention or antibodies of the invention with either an antibody containing sample or an antigen containing sample from the animal and detecting the presence of binding of either the antibodies in the sample with the cells or fractions of the invention or the binding of the antigens in the sample with the antibodies of the invention, the presence of binding indicating the presence of a parasite in the animal. In addition, the invention provides a method of culturing parasite cell populations in vitro comprising culturing a parasite in parasite culture medium under conditions which allow for decomposition and/or degradation of the cuticle layer of the parasite such that cellular buds are produced; disrupting the culture to cause the cellular buds to shear from the cuticle layer; and culturing the parasite cellular buds in cell culture medium. Finally provided is a population of differentiated nematode cells capable of prolonged culture in vitro.
The NETs will be detected and quantified by CMF on the remaining EDTA tube collected to perform the blood count (NFS), using the method in place in the laboratory, adapted from the method initially described by Gavillet et al. The analyses will be carried out on a Fortessa LSR cytometer (Becton Dickinson), the antibodies used are specific to NET components: citrullinated H3 anti-histone in indirect labelling coupled APC, PE myeloperoxidase and Hoescht 34580 as DNA marker. The level will be measured in NETs/µL of whole blood as a function of the white blood cell count (Sysmex XN-3000). In parallel, other parameters associated with ETV risk will be evaluated: NFS on Sysmex-XN PLC, D-dimers, FVIII and MP. The assays of PM, D-dimers and FVIII will be performed specifically as part of the project, the other parameters will be measured as part of routine patient management and will not result in any additional constraints or costs. Biomarker assays will be performed at the time of cancer diagnosis on the EDTA and citrate tubes collected for NFS and TP/TCA respectively as part of routine care.
A method is provided of identifying genes associated with poor clinical outcomes for a particular cancer. Genes encoding a comorbidity associated with a poor clinical outcomes for a particular cancer are identified in a cohort of patients with the cancer. Gene alterations and mutations associated with the comorbidities are determined. Gene expression level associated with the comorbidities are normalized against the expression level of a reference set of RNA transcripts in patients without the cancer or comorbidity. A statistical analysis compares the pathological gene expression level with normal gene expression level to create a database of statistically significant genes wherein the expression level of the abnormal genes is negatively associated with worse outcomes for the particular cancer. The method can be used to stage cancer, estimate prognosis, and for the design of therapeutic interventions by treating the comorbidity.
PROBLEM TO BE SOLVED: To obtain an easily takable powdery or solid preparation having high stability, safety and quality and free from the deterioration of the quality in distribution and storage by adding relatively small amounts of different kinds of surfactants to cyclosporin. SOLUTION: The objective preparation is produced by finely pulverizing cyclosporin, adding an anionic surfactant, thoroughly mixing the mixture and adding a nonionic surfactant to the mixture. The anionic surfactant is preferably sodium laurylsulfate and the nonionic surfactant is preferably a glycerol fatty acid ester or glycerol monostearate. The total amount of the surfactants is preferably 0.5-3 pts.wt. based on 1 pt.wt. of cyclosporin and the amount of the nonionic surfactant is preferably 0.5-2 pts.wt. based on 1 pt.wt. of the anionic surfactant. Cyclosporin A is widely used among the cyclosporin group as an immunosuppressing agent mainly for improving the percentage of success of organ transplantation.
Two randomized placebo-controlled clinical trials (Trial 1 and Trial 2) with similar designs were conducted to evaluate the efficacy of SOLOSEC 2 gram for the treatment of bacterial vaginosis. A diagnosis of bacterial vaginosis was defined as all of (a) the presence of an off-white (milky or gray), thin, homogeneous vaginal discharge; (b) a vaginal pH ≥ 4.7; (c) the presence of Clue cells ≥ 20% of the total epithelial cells on a microscopic examination of the vaginal saline wet mount; (d) a positive "whiff" test (detection of amine odor on addition of 10% KOH solution to a sample of the vaginal discharge); and (e) a Nugent score ≥ 4.

Trial 1 enrolled 144 non-pregnant female patients aged 19 to 54 years and Trial 2 enrolled 189 non-pregnant females aged 18 to 54 years. Black or African American subjects in both trials were 54%. Efficacy was assessed by clinical outcome evaluated 21 to 30 days following a single dose of SOLOSEC. A clinical responder was defined as "normal" vaginal discharge, negative "whiff" test, and clue cells <20%. Additional endpoints included Nugent score cure (Nugent score of 0-3) and therapeutic outcome. A therapeutic responder was defined as a clinical responder with a Nugent score cure. In Trial 2, the endpoints were also assessed at Day 7-14.

In both trials, a statistically significantly greater percentage of patients experienced clinical response, Nugent score cure, and therapeutic response at 21 to 30 days following a single dose of SOLOSEC compared to placebo. Statistically significant results for the endpoints were also achieved at Day 7-14 in Trial 2.

The percentage of patients with clinical response was also consistently higher in both trials in the SOLOSEC arm compared to placebo among all subsets of patients: number of prior episodes of bacterial vaginosis (≤ 3 episodes and ≥ 4 episodes) in past 12 months, baseline Nugent score (score 4-6 and score 7-10), and race (Black/African American and White). Tables 3 and 4 describe the efficacy of SOLOSEC in the treatment of bacterial vaginosis.
INTRODUCTION: The persistent patency of the ductus arteriosus frequently occurs in premature neonates and can cause infective endocarditis (IE) or ductal endarteritis (DE) during sepsis. Even though neonatal IE and DE are believed to be a rare eventuality, their incidence has been increasing in the last decades due to the improved survival of even more preterm babies, favored by highly invasive procedures and therapies. In parallel, antimicrobial resistance is another rising problem in neonatal intensive care units, which frequently compels to treat infections with broad-spectrum or last generation antibiotics.
CASE PRESENTATION: We report the case of a preterm neonate affected by patent ductus arteriosus-associated DE that followed an episode of sepsis caused by a high-level aminoglycoside-resistant enterococcus. The neonate was successfully treated with the synergistic combination of ampicillin and cefotaxime.
DISCUSSION: IE and patent ductus arteriosus-associated DE are rising inside neonatal intensive care units and neonatologists should be aware of these conditions. Enterococcal IE and patent ductus arteriosus-associated DE sustained by high-level aminoglycoside-resistant strains can be successfully treated with the synergistic combination of ampicillin and cefotaxime even in preterm neonates.
Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
The management of acute burn pain poses significant challenges. Regional techniques have become increasingly popular in perioperative burn pain management. Continuous nerve block catheters are particularly useful for split-thickness skin grafts where donor site pain can exceed that of the burn-injured site. Donor skin is frequently harvested from the anterolateral thigh. The fascia iliaca (FI) compartment block provides blockade of both the lateral femoral cutaneous nerve and the femoral nerve, and thus, it is a useful modality for burn donor pain. Our institution initiated a protocol in which continuous FI catheters were placed in patients undergoing split-thickness skin grafting of the anterolateral thigh. This retrospective review seeks to assess the impact of this modality on postoperative pain scores and opioid requirements. Oral morphine equivalent (OME) administration was significantly lower in the FI group than the control group, starting with POD 0, which is the day of the FI catheter insertion (188 vs 327 mg, P < .001). Over the next 4 postoperative days (PODs), OME administration remained lower in the FI group compared to control patients, although not statistically significant on PODs 3-4. There was a significant difference in OME administered between the FI group and the control group on POD 5 (159.5 vs 209.2 mg, P < .05). Our retrospective study evaluating the role of FI catheters in burn patients undergoing split-thickness skin grafting surgery showed significantly lower opioid consumption on PODs 1-5 compared to patients without an FI catheter.
The invention concerns the discovery of the surprising and unexpected therapeutic effects of hydroxyl ions. The observed medicinal properties of these ions are both novel and broad in scope. The acute corrosive effects and toxicity of hydroxyl ions on living tissue has previously overwhelmed their therapeutic attributes. Unique hydroxyl ion modulating compounds have been discovered and are within the scope of the invention. When used appropriately as companions with hydroxyl ions, these modulating compounds obviate and attenuate the harmful effects of hydroxyl ions,unmasking and revealing their previously unknown and undemonstratable therapeutic properties. These hydroxyl ion modulating compounds do not significantly interfere with the surprising and unexpected therapeutic benefits of the hydroxyl ions. The novel hydroxyl ion modulating compounds are generally characterized as N,N-disubstituted-aminoacetate salts and substituted N,N-substituted-aminoacetate salts. The invention includes compositions and methods of treatment using hydroxyl ions and the companion hydroxyl ion modulating compounds. These compositions and methods of treatment provide a wide variety of therapeutic effects including dermal effects (such as wound healing), ocular effects, oral therapeutic effects, ear, nose and throat therapeutic effects and internal therapeutic effects. Processes for preparing the present hydroxyl ion modulating components are also disclosed and are within the scope of the present invention.
Increasing environmental genotoxic chemicals have been shown to induce epigenetic alterations. However, the interaction between genetics and epigenetics in chemical carcinogenesis is still not fully understood. Here, we constructed an in vitro human lung carcinogenesis model (16HBE-T) by treating human bronchial epithelial cells with a typical significant carcinogen benzo(a)pyrene (BaP). We identified a novel circular RNA, circ0087385, which was overexpressed in 16HBE-T and human lung cancer cell lines, as well as in lung cancer tissues and serum exosomes from lung cancer patients. The upregulated circ0087385 after exposure to BaP promoted DNA damage in the early stage of chemical carcinogenesis and affected the cell cycle, proliferation, and apoptosis of the malignantly transformed cells. Overexpression of circ0087385 enhanced the expression of cytochrome P450 1A1 (CYP1A1), which is crucial for metabolically activating BaP. Interfering with circ0087385 or CYP1A1 reduced the levels of ultimate carcinogen benzo(a)pyrene diol epoxide (BPDE) and BPDE-DNA adducts. Interfering with CYP1A1 partially reversed the DNA damage induced by high expression of circ0087385, as well as decreased the level of BPDE and BPDE-DNA adducts. These findings provide novel insights into the interaction between epigenetics and genetics in chemical carcinogenesis which are crucial for understanding the epigenetic and genetic toxicity of chemicals.
The phase I study is a dose-escalation study using a standard 3+3 design. The regimen involves 3-week cycles with escalated doses of nab-paclitaxel (80-120 mg/m2 on days 1 and 8) and fixed doses of sintilimab (200 mg on day 1) and S-1 (based on body-surface area on day 1 to 14). The primary endpoints are safety and determination the recommended dose in the subsequent phase II study. In the phase II trial, the primary endpoint is 3-year relapse-free survival (RFS). Secondary endpoints are 5-year overall survival (OS), 3-year OS, 5-year RFS, and quality of life. Exploratory endpoint is time to peritoneal metastasis. Adverse events are monitored and graded according to the Common Terminology Criteria for Adverse Events version 4.0.
Fatigue is a subjective experience that can affect all individuals. It is a protective symptom against physical or psychological stress for healthy individuals. However, it can negatively affect the performance of individuals in activities of daily living. In the clinic, fatigue is assessed by self-reported scales. Different fatigue scales have some advantages and disadvantages compared to each other. Moreover, it is stated that only one scale cannot fully measure the fatigue of individuals in different health status, therefore different scales have been developed.Chalder Fatigue Scale (CFS) is an easy-to-understand, short, fast and useful fatigue scale that evaluates fatigue with two dimensions (physical and mental) and enable individuals to express perceived fatigue clearly. Psychometric properties of CFS have been investigated in general population and different disease groups but not in only healthy young adults.
<P>PROBLEM TO BE SOLVED: To produce a plant material having an improved additional value by fermenting the plant material by using microorganisms such as lactic bacteria and yeasts, and to produce a useful food, cosmetic or the like from the product.  <P>SOLUTION: The raw or dried plant material is optionally finely pulverized, and if necessary, water and a sugar source at a required smallest amount for the fermentation is added to the plant material. The resultant plant material is fermented by the microorganisms such as the lactic bacteria and the yeasts. The product is dried and formed into a powder as it is or after heating, and the powder is subjected to processing. The plants fermented by the microorganisms contain live bacteria, killed bacteria and products of the microorganisms which are considered to be useful in recent years, but hardly contain a culture medium and a nutritive value which are considered to be unnecessary. The fermented product has excellent processability to a food and a cosmetic, and is extremely useful.  <P>COPYRIGHT: (C)2003,JPO
Fathers' involvement in their children's lives has received increased attention in recent years. In response, support has grown for responsible fatherhood programs aimed at improving the quantity and quality of fathers' involvement. Research on these programs has concluded that factors such as fathers' parenting skills, co-parenting relationship quality, and socioeconomic status all impact fathers' ability to contribute to their children's growth and development. Using this previous research as a foundation, the Stepping Up 4 Your Child project will go beyond traditional fatherhood initiatives by integrating the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement. To do so, the University of Louisville's Kent School of Social Work will leverage its existing relationship with the Kentucky Office of Child Support Enforcement. Specifically, through Stepping Up 4 Your Child, non-custodial fathers will be provided with a comprehensive, solution-oriented program featuring group based parent education and individualized case management to help them achieve financial independence, increase their parenting skills, and develop a co-parenting alliance. Given that each of these focus areas have all been cited as three of the strongest predictors of paternal engagement, Stepping Up 4 Your Child and the results of its evaluation will have significant implications for the families it serves, as well as the practitioners, researchers, and policymakers interested in responsible fatherhood. 1
OBJECTIVE: We aimed to conduct a comprehensive meta-analysis of the association between methionine synthase reductase (MTRR) c.66A>G variant and recurrent pregnancy loss (RPL) susceptibility.
METHODS: We conducted a comprehensive systematic search of literature published before February 25, 2023 using PubMed, Embase, Web of Science, and Cochrane Library. Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of the included studies. The odds ratio (OR) was used to estimate the association between MTRR c.66A>G variant and RPL susceptibility. The I squared (I2) statistic and Q statistic were used to assess the heterogeneity among the included studies. And Begg's test and Egger's regression were then used to test the existence of publication bias.
RESULTS: In this meta-analysis, we included 10 studies comprising 1842 RPL cases and 2173 healthy pregnant women to investigate the relationship between MTRR c.66A>G variants and the susceptibility of RPL. In the overall population analysis, MTRR c.66A>G variant was not significantly associated with the risk of RPL in different comparison models. Since 9 of the included studies were conducted in Asia, we performed analyses separately for Asian populations, including a total of 1855 cases and 2127 controls. Results showed, in Asian populations, there is no significant correlation between c.66A>G variant and the risk of RPL. Subgroup analyses according to ethnicity and country yielded similar results.
CONCLUSION: Our findings suggested that the MTRR c.66A>G variant was not significantly associated with the risk of RPL.
OBJECTIVE: The Visiopharm artificial intelligence (AI) algorithm for oestrogen receptor (ER) immunohistochemistry (IHC) in whole slide images (WSIs) has been successfully validated in surgical pathology. This study aimed to assess its efficacy in cytology specimens.
METHODS: The study cohort comprised 105 consecutive cytology specimens with metastatic breast carcinoma. ER IHC WSIs were seamlessly integrated into the Visiopharm platform from the Image Management System (IMS) during our routine digital workflow, and an AI algorithm was employed for analysis. ER AI scores were compared with pathologists' manual consensus scores. Optimization steps were implemented and evaluated to reduce discordance.
RESULTS: The overall concordance between pathologists' scores and AI scores was excellent (99/105, 94.3%). Six cases exhibited discordant results, including two false-negative (FN) cases due to abundant histiocytes incorrectly counted as negatively stained tumour cells by AI, two FN cases owing to weak staining, and two false-positive (FP) cases where pigmented macrophages were erroneously counted as positively stained tumour cells by AI. The Pearson correlation coefficient of ER-positive percentages between pathologists' and AI scores was 0.8483. Optimization steps, such as lowering the cut-off threshold and additional training using higher input magnification, significantly improved accuracy.
CONCLUSIONS: The automated ER AI algorithm demonstrated excellent concordance with pathologists' assessments and accurately differentiated ER-positive from ER-negative metastatic breast carcinoma cytology cases. However, precision in identifying tumour cells in cytology specimens requires further enhancement.
Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
Periodontitis is a chronic disease characterized by progressive loss of tooth-supporting tissues. It is adversely affecting function, esthetic, and general wellbeing. Oral health related quality of life (OHRQoL) is the part of quality of life which is affected by oral cavity-related status. Majority of clinical studies emphasize on periodontal outcomes after periodontal therapy. However, tangible outcomes perceived by the patient such as need for re-treatment, tooth survival, and OHRQoL are mostly neglected. OHRQoL is mainly measured by using self-reported questionnaires and the most commonly used one is Oral Health Impact Profile (OHIP).

Nonsurgical periodontal therapy (NSPT) is the gold-standard technique for treating shallow to moderately deep periodontal pockets. The principle of this technique is based on mechanically disrupting subgingival dysbiotic biofilm, consequently; restoring homeostasis and healthy state of periodontal tissues. Indeed, halting progressive periodontitis is a major contributor for improving oral health and increasing tooth survival rate which are positively perceived by the patients. Previous studies consistently reporting improvement of OHRQoL following periodontal treatment. Therefore, this study aimed to investigate the impact of NSPT on OHRQoL for Stage (S)2 and S3 periodontitis patient and the factors predicting the outcomes.
PURPOSE:To obtain a bathing agent having effects, such as enhancement of bathing effects, due to dissolving sound by sealing a high-pressure gas constituted so as to produce bursting sound in dissolving in use thereof in a bathtub, etc., in a bathing agent base soluble with water, heat, etc. CONSTITUTION:A bathing agent obtained by sealing a high-pressure gas (e.g., oxygen, gaseous carbon dioxide, nitrogen gas or air) in a bathing agent base (e.g., NaHCO3, Na2SO4, Na2CO3 or NaCl) soluble with water or heat. Saccharides (e.g. fructose, xylose, sucrose or lactose) are preferably blended in the above-mentioned base so as to regulate duration of bursting sound, sound quality, etc., in dissolving. The afore-mentioned bathing agent has the following effects. The hermetically sealed high-pressure gas is capable of breaking the base, simultaneously producing bursting sound, generating ultrasonic waves and enhancing effects of systemic cleaning and medical ingredients. Bathing can be economically carried out while enjoying sounds without requiring a special bathtub apparatus for jetting out bubbles, etc.